Israel has experienced serious societal disruption – with plans to overhaul the judiciary, COVID and notably the conflict in Gaza – but its ability to develop innovative healthtech has been fairly und
Israel has experienced serious societal disruption – with plans to overhaul the judiciary, COVID and notably the conflict in Gaza – but its ability to develop innovative healthtech has been fairly und
Biopharma merger and acquisition value for the first quarter of 2025 reached $38.4bn from 41 transactions, 22 of which had disclosed values. Making up almost 38% of that total was Johnson & Johnso
Biopharma merger and acquisition value for the fourth quarter of 2024 reached $9.4bn from 34 transactions, 15 of which had disclosed values. At the top was H. Lundbeck’s $2.6bn purchase of publicly tr